ME02403B - POSTUPCI ZA PREČIŠĆAVANJE TRANS-(-)-Δ9-TETRAHIDROKANABINOLA l TRANS-(+) - Δ9 - TETRAHIDROKANABINOLA - Google Patents

POSTUPCI ZA PREČIŠĆAVANJE TRANS-(-)-Δ9-TETRAHIDROKANABINOLA l TRANS-(+) - Δ9 - TETRAHIDROKANABINOLA

Info

Publication number
ME02403B
ME02403B MEP-2016-55A MEP5516A ME02403B ME 02403 B ME02403 B ME 02403B ME P5516 A MEP5516 A ME P5516A ME 02403 B ME02403 B ME 02403B
Authority
ME
Montenegro
Prior art keywords
tetrahydrocannabinol
trans
phase
composition
alcoholic
Prior art date
Application number
MEP-2016-55A
Other languages
English (en)
Inventor
Arie L Gutman
Gennady A Nisnevich
Igor Rukhman
Boris Tishin
Marina M Etinger
Irina M Fedotev
Boris M Pertsikov
Ram Khanolkar
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35789123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02403(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of ME02403B publication Critical patent/ME02403B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Claims (11)

1.Postupak za uklanjanje nečistoća iz kompozicije koja sadrži trans-(-) Δ9-tetrahidrokanabinol i trans-(+)-Δ9-tetrahidrokanabinol pre kristalizacije (±)-Δ9-tetrahidrokanabinola, a postupak obuhvata:(a) dovođenje u kontakt trans-(-)-Δ9-tetrahidrokanabinola i trans-(+)-Δ9 tetrahidrokanabinola sa prvim organskim rastvaračem koji se ne meša sa vodom, alkoholom koji se meša sa vodom, vodom, i hidroksidom alkalnog metala, na taj način obrazujući bifaznu kompoziciju koja sadrži (i) prvu organski fazu i (ii) alkoholnu-kaustičnu fazu koja sadrži trans-(-)- Δ9-tetrahidrokanabinol i trans-(+)-Δ9-tetrahidrokanabinol;(b) odvajanje alkoholno-kaustične faze koja sadrži trans-(-)-Δ9-tetrahidrokanabinol i trans-(+)-Δ9-tetrahidrokanabinol od prve organske faze;(c) dovođenje u kontakt alkoholno-kaustične faze sa kiselinom da bi se dobila alkoholna faza tretirana kiselinom.
2.Postupak za uklanjanje nečistoća iz kompozicije koja sadrži trans-(-)-Δ9-tetrahidrokanabinol ili trans-(+)-Δ9-tetrahidrokanabinol pre kristalizacije (±)-Δ9-tetrahidrokanabinola, a postupak obuhvata: (a) dovođenje u kontakt trans-(-)-Δ9-tetrahidrokanabinola ili trans-(+)-Δ9-tetrahidrokanabinola sa prvim organskim rastvaračem koji se ne meša sa vodom, aloholom koji se meša sa vodom, vodom, i hidroksidom alkalnog metala, tako obrazujući bifaznu kompoziciju koja sadrži (i) prvu ogransku fazu, i (ii) alkoholno-kaustičnu fazu koja sadrži trans-(-)-Δ9-tetrahidrokanabinol ili trans-(+)-Δ9-tetrahidrokanabinol; (b) odvajanje alkoholno-kaustične faze koja sadrži trans-(-)-Δ9-tetrahidrokanabinol ili trans-(+)-Δ9-tetrahidrokanabinol od prve organske faze; (c) dovođenje u kontakt alkoholno-kaustične faze sa kiselinom da bi se dobila alkoholna faza tretirana kiselinom.
3.Postupak prema zahtevu 1 ili 2, gde je kiselina limunska kiselina ili sirćetna kiselina.
4.Postupak prema bilo kom od zahteva 1 do 3, gde je kiselina dodata u količini dovoljnoj da se postigne pH od 5 do 9.
5.Postupak prema bilo kom od zahteva 1 do 4, koji obuhvata dodatni korak: (d) dovođenja u kontakt alkoholne faze tretirane sa drugim organskim rastvaračem koji se ne meša sa vodom da bi se obrazovala (i) druga organska faza koja sadrži Δ9-tetrahidrokanabinol i (ii) alkoholna faza tretirana kiselinom.
6.Postupak prema zahtevu 5, koji obuhvata dodatni korak (e) odvajanja druge organske faze od alkoholne faze koja je tretirana kiselinom.
7.Postupak dobijanja kristalnog (±)-Δ9-tetrahidrokanabinola koji obuhvata: omogućavanje kristalizacije trans-(-)-Δ9-tetrahidrokanabinola i trans-(+)-Δ9-tetrahidrokanabinola iz prve kompozicije koja sadrži trans-(-)-Δ9-tetrahidrokanabinol, trans-(+)-Δ9-tetrahidrokanabinol, i nepolarni organski rastvarač da bi se dobio kristalni (±)-Δ9-tetrahidrokanabinol, pri čemu je prva kompozicija dobijena (a) izvođenjem postupka prema bilo kom od zahteva 1 do 6, (b) odvajanjem Δ9-tetrahidrokanabinola iz dobijene faze koja sadrži Δ9-tetrahidrokanabinol; i (c) dovođenjem u kontakt Δ9-tetrahidrokanabinola iz koraka (b) sa nepolarnim organskim rastvaračem i opciono njegovim enantiomerom da bi se obrazovala prva kompozicija.
8.Postupak prema zahtevu 7, gde je nepolarni organski rastvarač ravnolančani ili razgranati (C4-C10)alifatični ugljovodonik, (C4-C10)cikloalifatični ugljovodonik, ili bilo koja njihova smeša, gde je ravnolančani ili razgranti ugljovodonik poželjno pentan, heksan, heptan, izooktan, ili bilo koja njihova smeša, a poželjnijo je n-heptan.
9.Postupak dobijanja kompozicije trans-(-)-Δ9-tetrahidrokanabinola, koji obuhvata: omogućavanje odvajanja kompozicije koja sadrži (±)-Δ9-tetrahidrokanabinol i eluacioni rastvarač na hiralnoj stacionarnoj fazi da se dobije kompozicija trans-(-)-Δ9-tetrahidrokanabinola, ili kompozicije trans-(+)-Δ9-tetrahidrokanabinola, koji obuhvata: omogućavanje odvajanja kompozicije koja sadrži (±)-Δ9-tetrahidrokanabinol i eluacioni rastvarač na hiralnoj stacionarnoj fazi da bi se dobila kompozicija trans-(+)-Δ9-tetrahidrokanabinola, gde je (±)-Δ9-tetrahidrokanabinol dobijen iz kristalnog (±)-Δ9-tetrahidrokanabinola, i gde je kristalni (±)-Δ9-tetrahidrokanabinol dobijen postupkom prema zahtevu 7 ili 8.
10.Postupak prema bilo kom od zahteva 7 do 9, gde trans-(-)-Δ9-tetrahidrokanabinol je prisutan u prvoj kompoziciji u količini od 0.75 do 1.25 molarnih ekvivalenata, poželjno od 0.9 do 1.1 molarnih ekvivalenata, poželjnije od 0.95 do 1.25 molarnih ekvivalenata i čak poželjnije 1 molarni ekvivalent po molarnom ekvivalentu trans-(+)-Δ9-tetrahidrokanabinola.
11.Postupak prema bilo kom od zahteva 7 do 10, gde (±)-Δ9-tetrahidrokanabinol obuhvata bar 95% u odnosnu na težinu, poželjno bar 98% u odnosu na težinu i poželjnije bar 99% u odnosu na težinu trans-(-)-Δ9-tetrahidrokanabinola i trans-(+)-Δ9-tetrahidrokanabinola u odnosu na ukupnu količinu kanabinoida.
MEP-2016-55A 2004-11-22 2005-11-18 POSTUPCI ZA PREČIŠĆAVANJE TRANS-(-)-Δ9-TETRAHIDROKANABINOLA l TRANS-(+) - Δ9 - TETRAHIDROKANABINOLA ME02403B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63055604P 2004-11-22 2004-11-22
EP10179374.3A EP2356987B1 (en) 2004-11-22 2005-11-18 Methods for purifying trans-(-)-delta9-tetrahydrocannabinol and trans-(+)-delta9-tetrahydrocannabinol

Publications (1)

Publication Number Publication Date
ME02403B true ME02403B (me) 2016-09-20

Family

ID=35789123

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2015-186A ME02306B (me) 2004-11-22 2005-11-18 Postupci za prečišćavanje trans-(-)-Δ⁹-tetrahidrokanabinola i trans-(+)- Δ⁹-tetrahidrokarabinola
MEP-2016-55A ME02403B (me) 2004-11-22 2005-11-18 POSTUPCI ZA PREČIŠĆAVANJE TRANS-(-)-Δ9-TETRAHIDROKANABINOLA l TRANS-(+) - Δ9 - TETRAHIDROKANABINOLA

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2015-186A ME02306B (me) 2004-11-22 2005-11-18 Postupci za prečišćavanje trans-(-)-Δ⁹-tetrahidrokanabinola i trans-(+)- Δ⁹-tetrahidrokarabinola

Country Status (30)

Country Link
US (6) US8383842B2 (me)
EP (3) EP1824475B1 (me)
JP (3) JP4995728B2 (me)
KR (1) KR100919719B1 (me)
CN (2) CN102151259A (me)
AR (1) AR054989A1 (me)
AT (1) ATE500824T1 (me)
AU (2) AU2005305944B2 (me)
BR (1) BRPI0519803A2 (me)
CA (2) CA2587957C (me)
CY (1) CY1111471T1 (me)
DE (1) DE602005026852D1 (me)
DK (3) DK2356987T3 (me)
EA (1) EA012299B1 (me)
ES (3) ES2556802T3 (me)
HR (3) HRP20110385T1 (me)
HU (2) HUE025904T2 (me)
IL (1) IL183306A (me)
ME (2) ME02306B (me)
MX (1) MX2007006104A (me)
NO (1) NO331831B1 (me)
NZ (1) NZ556038A (me)
PL (3) PL2289509T3 (me)
PT (2) PT2289509E (me)
RS (3) RS54338B1 (me)
SI (3) SI2289509T1 (me)
TW (2) TWI369203B (me)
UA (1) UA88491C2 (me)
WO (1) WO2006053766A1 (me)
ZA (1) ZA200706837B (me)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI369203B (en) * 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
CA2623723A1 (en) 2005-09-29 2007-04-12 Amr Technology, Inc. Process for production of delta-9-tetrahydrocannabinol
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
GB0702895D0 (en) * 2007-02-14 2007-03-28 Resolution Chemicals Ltd Delta 9 tetrahydrocannabinol derivatives
GB0703284D0 (en) 2007-02-20 2007-03-28 Resolution Chemicals Ltd Delta 9 - tetrahydrocannabinol processing
CA2751741C (en) * 2008-02-06 2018-07-10 Mallinckrodt Inc. Process for the preparation of (-) -delta 9-tetrahydrocannabinol
WO2014030053A1 (en) 2012-08-20 2014-02-27 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
US10155708B2 (en) 2015-01-22 2018-12-18 Phytoplant Research S.L. Methods of purifying cannabinoids, compositions and kits thereof
US11034639B2 (en) 2015-01-22 2021-06-15 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
US10207198B2 (en) 2015-01-22 2019-02-19 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
CN106268657A (zh) * 2015-05-14 2017-01-04 株式会社大赛璐 光学异构体用分离剂
US10059683B2 (en) 2015-07-10 2018-08-28 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
PL3455213T3 (pl) * 2016-05-13 2022-04-04 Symrise Ag Sposób oczyszczania związków kannabinoidowych przez symulowaną chromatografię z ruchomym złożem
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CN106810426B (zh) * 2016-12-29 2020-05-08 暨明医药科技(苏州)有限公司 一种大麻二酚的合成方法
US11213558B2 (en) 2017-05-17 2022-01-04 Orochem Technologies, Inc. CBX extraction-isolation process
US10189762B1 (en) 2017-07-07 2019-01-29 Orochem Technologies, Inc. Process for purification and separation of cannabinoids, from dried hemp and cannabis leaves
SG11202001725SA (en) * 2017-09-01 2020-03-30 Pureform Global Inc Synthetic cannabidiol compositions and methods of making the same
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
EP3762375A4 (en) * 2018-03-07 2022-02-16 Socati Technologies-Oregon, LLC CONTINUED ISOLATION OF CANNABIDIOL AND CONVERSION OF CANNABIDIOL INTO DELTA-8-TETRAHYDROCANNABINOL AND DELTA-9-TETRAHYDROCANNABINOL
US11851415B2 (en) 2018-03-07 2023-12-26 Cleen Technology Inc. Continuous isolation of cannabidiol and cannabinoids and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol
US11192870B2 (en) 2018-03-07 2021-12-07 Socati Technologies—Oregon, Llc Continuous isolation of cannabidiol and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol
EP4620940A3 (en) * 2018-06-28 2025-12-17 Symrise AG Synthesis of (+)-cannabinoids and their therapeutic effects
WO2020028198A1 (en) 2018-08-03 2020-02-06 Biomass Oil Separation Solutions, Llc Processes and apparatus for extraction of substances and enriched extracts from plant material
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
US11993563B2 (en) 2018-10-31 2024-05-28 Enantia S.L. Solid compositions of cocrystals of cannabinoids
EP3653596A1 (en) * 2018-11-14 2020-05-20 Indena S.p.A. Continuous flow synthesis of cannabidiol
CN109734554B (zh) * 2019-02-25 2021-11-23 江苏暨明医药科技有限公司 一种反式-薄荷基-2,8-二烯-1-醇的合成工艺
CN111943813B (zh) * 2019-05-17 2023-04-14 上海特化医药科技有限公司 大麻二酚类化合物的制备方法
WO2020248058A1 (en) 2019-06-11 2020-12-17 Canopy Growth Corporation Improved methods for converting cannabidiol into delta 8-tetrahydrocannabinol
WO2020248062A1 (en) * 2019-06-11 2020-12-17 Canopy Growth Corporation Improved methods for cannabinoid isomerization
US10799546B1 (en) 2019-07-26 2020-10-13 Biomass Oil Separation Solutions, Llc Modular, integrated process and apparatus for extracting, refining and remediating active substances from plant material
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
CA3158415A1 (en) * 2019-10-21 2021-04-29 Esolate Ltd Compositions comprising superfine compounds and production thereof
GB2588456B (en) * 2019-10-25 2023-02-01 Gw Res Ltd Cannabinoid compound
GB2588455B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
GB2588457B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
WO2021181420A1 (en) 2020-03-12 2021-09-16 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) Process for the synthesis of cannabidiol and intermediates thereof
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
WO2022125966A1 (en) 2020-12-10 2022-06-16 Orochem Technologies Inc. Process for removing thc from cannabinoids
CN113336705B (zh) * 2021-08-09 2021-12-10 中国农业科学院农产品加工研究所 一种大麻二酚-2-咪唑-1-甲酸酯及其应用
US20260049067A1 (en) 2022-08-05 2026-02-19 Salud & Semillas, S.L. CANNABINOID SYNTHESIS STARTING OUT FROM OLIVETOL AND TERPENE IN DICHLOROMETHANE WITH FeCl 3 * 6H2O AS CATALYST
CN115583933B (zh) * 2022-10-31 2024-02-06 暨明医药科技(苏州)有限公司 一种高纯度四氢大麻素同系物的制备方法
CN115784836A (zh) * 2022-12-08 2023-03-14 南京康立瑞生物科技有限公司 一种高选择性的制备反式-薄荷基-2,8-二烯-1-醇的方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507885A (en) 1966-03-25 1970-04-21 Hoffmann La Roche 3-alkyl-6h-dibenzo(b,d)pyrans
CH481911A (de) 1967-05-19 1969-11-30 Theodor Dr Petrzilka Verfahren zur Herstellung von tricyclischen Verbindungen
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3668224A (en) 1970-07-02 1972-06-06 Theodor Petrzilka PROCESS OF PRODUCING 6a, 10a-TRANS-6a,7,8,10a-TETRAHYDRODIBENZO (b,d)-PYRANS
US4025516A (en) 1975-06-23 1977-05-24 The John C. Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
US4381399A (en) 1981-12-21 1983-04-26 Aerojet-General Corporation Purification of tetrahydrodibenzo[b,d]pyrans from crude synthetic mixtures
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE4100441A1 (de) 1991-01-09 1992-07-16 Mack Chem Pharm Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
US6703418B2 (en) 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
ES2247604T3 (es) 1995-06-12 2006-03-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6328992B1 (en) 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6365416B1 (en) 1998-10-26 2002-04-02 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
US6730519B2 (en) 1998-10-26 2004-05-04 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
FI990915A0 (fi) 1999-04-23 1999-04-23 Orion Yhtymae Oyj Jauheinhalaattori
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6747058B1 (en) 1999-08-20 2004-06-08 Unimed Pharmaceuticals, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
GB2368061B (en) 2000-10-20 2005-05-11 Gw Pharmaceuticals Ltd Dose dispensing apparatus
AU2738302A (en) 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
WO2002070506A2 (en) 2001-03-07 2002-09-12 Websar Innovations Inc. Conversion of cbd to δ8-thc and δ9-thc
US20030050334A1 (en) 2001-04-30 2003-03-13 Murty Ram B. Process for extraction of Delta-9-Tetrahydrocannabinol and other related cannabinoids and preparation of specific strength marijuana cigarettes
GB0112752D0 (en) 2001-05-25 2001-07-18 Johnson Matthey Plc Synthesis of cannabinoids
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
NZ534430A (en) 2002-02-01 2007-09-28 Resolution Chemicals Ltd Production of delta 9 tetrahydrocannabinol from plant material
AU2002242779A1 (en) 2002-02-21 2003-09-09 Timothee Biel Device for driving motor vehicles, in particular with hybrid propulsion
UA79281C2 (en) 2002-04-03 2007-06-11 Solvay Pharm Bv Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
CA2770448C (en) 2002-11-12 2014-03-25 Prairie Plant Systems Inc. Cannabinoid esters
US20040229939A1 (en) 2003-02-14 2004-11-18 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
BRPI0416268A (pt) 2003-11-05 2007-12-11 Unimed Pharmaceuticals Inc composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
GB0329635D0 (en) * 2003-12-23 2004-01-28 Johnson Matthey Plc Process for purifying trans-tetrahydrocannabinol
US7923558B2 (en) 2004-07-19 2011-04-12 Cilag Ltd. Method for obtaining pure tetrahydrocannabinol
GB0425445D0 (en) 2004-11-18 2004-12-22 Smithkline Beecham Corp Novel compositions
TWI369203B (en) * 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
DK2176208T3 (en) 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
US8642645B2 (en) * 2011-05-20 2014-02-04 Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids

Also Published As

Publication number Publication date
HK1154796A1 (en) 2012-05-04
ES2362288T3 (es) 2011-06-30
EP2289509B1 (en) 2015-10-14
US8937097B2 (en) 2015-01-20
PL1824475T3 (pl) 2011-09-30
CN101076329B (zh) 2011-08-10
KR100919719B1 (ko) 2009-10-06
CA2587957C (en) 2016-05-03
TW200633695A (en) 2006-10-01
HUE025904T2 (en) 2016-05-30
NZ556038A (en) 2009-12-24
US8383842B2 (en) 2013-02-26
PL2356987T3 (pl) 2016-09-30
US20160184261A1 (en) 2016-06-30
KR20070086529A (ko) 2007-08-27
US20130171259A1 (en) 2013-07-04
SI2356987T1 (sl) 2016-04-29
EP2356987A1 (en) 2011-08-17
EA200701123A1 (ru) 2007-12-28
BRPI0519803A2 (pt) 2009-03-17
SI2289509T1 (sl) 2016-01-29
MX2007006104A (es) 2007-07-11
PL2289509T3 (pl) 2016-04-29
ME02306B (me) 2016-06-20
DE602005026852D1 (de) 2011-04-21
SI1824475T1 (sl) 2011-06-30
JP2008520608A (ja) 2008-06-19
ES2556802T3 (es) 2016-01-20
PT2289509E (pt) 2015-12-23
ATE500824T1 (de) 2011-03-15
EP2289509A3 (en) 2011-08-10
IL183306A0 (en) 2007-09-20
ES2566480T3 (es) 2016-04-13
HK1109058A1 (en) 2008-05-30
HK1159500A1 (en) 2012-08-03
RS51706B (sr) 2011-10-31
AR054989A1 (es) 2007-08-01
TWI436991B (zh) 2014-05-11
TW201302722A (zh) 2013-01-16
TWI369203B (en) 2012-08-01
CA2587957A1 (en) 2006-05-26
AU2005305944B2 (en) 2010-03-04
NO20072964L (no) 2007-08-17
CY1111471T1 (el) 2015-08-05
JP2012180350A (ja) 2012-09-20
IL183306A (en) 2012-06-28
CN101076329A (zh) 2007-11-21
EP2289509A2 (en) 2011-03-02
EA012299B1 (ru) 2009-08-28
EP2356987B1 (en) 2016-01-06
JP5048448B2 (ja) 2012-10-17
HRP20110385T1 (hr) 2011-06-30
ZA200706837B (en) 2008-04-30
CA2921590A1 (en) 2006-05-26
US9278083B2 (en) 2016-03-08
JP4995728B2 (ja) 2012-08-08
US20150126596A1 (en) 2015-05-07
NO331831B1 (no) 2012-04-16
US20160184260A1 (en) 2016-06-30
AU2010200227A1 (en) 2010-02-11
EP1824475A1 (en) 2007-08-29
US20160199344A1 (en) 2016-07-14
AU2005305944A1 (en) 2006-05-26
US20090298930A1 (en) 2009-12-03
WO2006053766A8 (en) 2006-12-14
HRP20160300T1 (hr) 2016-04-22
US9675581B2 (en) 2017-06-13
WO2006053766A1 (en) 2006-05-26
RS54338B1 (sr) 2016-02-29
HUE027197T2 (en) 2016-10-28
RS54537B1 (sr) 2016-06-30
JP2008101000A (ja) 2008-05-01
DK2356987T3 (en) 2016-03-21
CA2921590C (en) 2019-09-24
DK2289509T3 (en) 2015-11-23
UA88491C2 (ru) 2009-10-26
US9744151B2 (en) 2017-08-29
PT1824475E (pt) 2011-06-01
HRP20151301T1 (hr) 2016-01-01
EP1824475B1 (en) 2011-03-09
CN102151259A (zh) 2011-08-17
DK1824475T3 (da) 2011-06-06

Similar Documents

Publication Publication Date Title
ME02403B (me) POSTUPCI ZA PREČIŠĆAVANJE TRANS-(-)-Δ9-TETRAHIDROKANABINOLA l TRANS-(+) - Δ9 - TETRAHIDROKANABINOLA
WO2019057994A1 (en) NOVEL COMPOSITION AND METHOD FOR PREPARING THE SAME
US11560364B2 (en) Methods for enriching alpha-tocotrienol from mixed tocol compositions
US9365800B2 (en) Method for producing composition containing highly unsaturated fatty acid alkyl ester
MY142041A (en) Extraction process for removal of impurities from mother liquor in the synthesis of carboxylic acid
NO20064430L (no) Fjerning av permanganatreduserende forbindelser fra en metanolkarbonyleringsprosesstrom
BRPI0500882A (pt) processo para fabricação de xilose de elevada pureza
MY145002A (en) Process for the production of acetic acid
UA91825C2 (ru) Способ уменьшения соединений, которые восстанавливают перманганат из потока карбонилирования метанола
WO2010010298A3 (fr) Procede de fabrication d'acide propionique bio-ressource a partir de glycerol
CN101427847B (zh) 一种提取津巴布韦烟草净油的制备方法及其应用
JP2003518476A (ja) 乳酸の連続的製造方法
ATE448239T1 (de) Destillatives verfahren zur gewinnung und auftrennung von phytosterolen und phytostanolen aus tallölpech
BR112022003258A2 (pt) Processos de extração e purificação à base de água para ácidos canabinoides
KR101341033B1 (ko) 조효소 q10의 분리 및 정제 방법
CN1951888A (zh) 一种从烟叶浸膏中提纯茄尼醇的方法
Torrance et al. New monoterpenes from Artemisia filifolla. Structure, synthesis, rearrangements and biosynthesis
JPS5933354B2 (ja) 補酵素qの製造法
CN104402800A (zh) 一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法
CN103626820B (zh) 一种高纯度羊毛脂胆固醇制备方法
CN108164398A (zh) 一种羟基酪醇合成工艺的改进方法
EP0159018A2 (en) Production of D-alpha-tocopherol from natural plant sources
CN102140067A (zh) 从辣椒精中提取纯化高纯度辣椒碱的方法
CN1208332C (zh) 天然生育酚提取工艺
CN102649771A (zh) 一种辣椒碱的制备方法